Novel double coated nanocapsules for intestinal delivery and enhanced oral bioavailability of tacrolimus, a P-gp substrate drug

被引:78
作者
Nassar, Taher [1 ]
Rom, Alona [1 ]
Nyska, Abraham [2 ]
Benita, Simon [1 ]
机构
[1] Hebrew Univ Jerusalem, Sch Pharm, Dept Pharmaceut, IL-91120 Jerusalem, Israel
[2] Tel Aviv Univ, Sackler Sch Med, Tel Aviv, Israel
关键词
Tacrolimus; Nanocapsules; P-gp; Oral absorption; Bioavailability; SMALL-BOWEL; GLYCOPROTEIN; ABSORPTION; INHIBITORS; TRANSPORT;
D O I
10.1016/j.jconrel.2008.08.021
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
This study proposes a new concept of double coated nanocapsules to improve the oral bioavailability of a P-glycoprotein (P-gp) substrate drug, tacrolimus, without modulating the physiological activity of the P-gp pump. Tacrolimus was incorporated in nanocapsules with different ratios of two polymethacrylate polymers followed by microencapsulation of these nanocapsules within hydroxypropylmethylcellulose using a spray drying technique. The influence of different formulations of tacrolimus administered orally to rats and pigs on the drug's absorption was investigated. Histopathological studies were performed on rats to follow the nanocapsule path in enterocytes. The novel formulations that released mostly drug loaded nanocapsules in the intestine were shown to enhance markedly the oral absorption of tacrolimus. The relative oral bioavailability of tacrolimus was 4.9 and 2.45 fold compared to the commercial product in rats and pigs respectively. Although there is no direct evidence that intact nanocapsules internalized in the enterocytes, numerous small oil cores were detected within the enterocytes showing the potential of P-gp substrates incorporated in such nanocarriers to escape the efflux pump. (C) 2008 Elsevier B.V. All rights reserved.
引用
收藏
页码:77 / 84
页数:8
相关论文
共 26 条
[1]   Itraconazole-tacrolimus drug interaction [J].
Cervelli, MJ ;
Russ, GR .
THERAPEUTIC DRUG MONITORING, 2003, 25 (04) :483-484
[2]   Lipid formulation strategies for enhancing intestinal transport and absorption of P-glycoprotein (P-gp) substrate drugs:: In vitro/in vivo case studies [J].
Constantinides, Panayiotis P. ;
Wasan, Kishor M. .
JOURNAL OF PHARMACEUTICAL SCIENCES, 2007, 96 (02) :235-248
[3]   A review of low-dose ritonavir in protease inhibitor combination therapy [J].
Cooper, CL ;
van Heeswijk, RPG ;
Gallicano, K ;
Cameron, DW .
CLINICAL INFECTIOUS DISEASES, 2003, 36 (12) :1585-1592
[4]   In vivo comparison of various polymeric and low molecular mass inhibitors of intestinal P-glycoprotein [J].
Foeger, Florian ;
Hoyer, Herbert ;
Kafedjiiski, Krum ;
Thaurer, Michael ;
Bernkop-Schuerch, Andreas .
BIOMATERIALS, 2006, 27 (34) :5855-5860
[5]  
Gerrard G, 2004, HAEMATOLOGICA, V89, P782
[6]   DRUG-INDUCED ENTEROPATHY CHARACTERIZED BY LIPID IN MACROPHAGES [J].
GRAY, JE ;
WEAVER, RN ;
SINKULA, AA ;
SCHURR, PE ;
MORAN, J .
TOXICOLOGY AND APPLIED PHARMACOLOGY, 1974, 27 (01) :145-157
[7]   Interpatient variability in bioavailability is related to the extent of absorption: Implications for bioavailability and bioequivalence studies [J].
Hellriegel, ET ;
Bjornsson, TD ;
Hauck, WW .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1996, 60 (06) :601-607
[8]   A primer on the mechanics of P-glycoprotein the multidrug transporter [J].
Hennessy, M. ;
Spiers, J. P. .
PHARMACOLOGICAL RESEARCH, 2007, 55 (01) :1-15
[9]   ORAL ABSORPTION OF FK506 IN RATS [J].
KAGAYAMA, A ;
TANIMOTO, S ;
FUJISAKI, J ;
KAIBARA, A ;
OHARA, K ;
IWASAKI, K ;
HIRANO, Y ;
HATA, T .
PHARMACEUTICAL RESEARCH, 1993, 10 (10) :1446-1450
[10]   Low bioavailability of cyclosporine microemulsion and tacrolimus in a small bowel transplant recipient - Possible relationship to intestinal P-glycoprotein activity [J].
Kaplan, B ;
Lown, K ;
Craig, R ;
Abecassis, M ;
Kaufman, D ;
Leventhal, J ;
Stuart, F ;
Meier-Kriesche, HU ;
Fryer, J .
TRANSPLANTATION, 1999, 67 (02) :333-335